November 2011

Dear Colleagues:
It is time for a new round of application for the IASLC Fellowship/Young Investigator Awards (please see below). We will encourage as many as possible to apply for these fellowships! The Fellowship Announcement will be announced in English, and a Chinese, Japanese and Spanish version of the announcement can be found on the IASLC website Guidelines to apply can be found on the website too. If someone needs help with the application, the IASLC Office is happy to help. Please contact,

Please pay attention to and plan for the soon upcoming meeting with AACR: Molecular Biology of Lung Cancer in San Diego, CA, January 2012 and the European Lung Cancer Conference (ELCC) with ESMO in Geneva, April 2012 as well as the Latin American Lung Cancer Conference in Rio de Janeiro in July 2012.

The IASLC President has on this stage finalized the different 2011-2013 committees.

The IASLC is currently in the process of implementation of the strategic plan.

While the IASLC Headquarters these days are preparing the move to a new space in a new building at the University of Colorado Campus, the organization is proud to announce that our new CFO/COO, Mr. John Wetherington will be starting December 1, 2011 (please see below presentation) The IASLC Executive Office and Board of Directors wish all of you, for whom it is relevant, a Happy Thanksgiving and upcoming Holiday Season!

Fred R. Hirsch, MD, PhD
Editor, IASLC Newsletter

Strategic Plan


IASLC Fellowship/Young Investigator Announcement/ IASLC/Prevent Cancer Foundation Fellowship Award 2012

IASLC Lung Cancer Fellowship Award
2 years duration

IASLC Young Investigators Award
2 years duration

IASLC/PCF Prevent Cancer Foundation Fellowship Award
2 years duration

The International Association for the Study of Lung Cancer is proud to announce the annual IASLC Fellowship and Young Investigators Programs.

Applications are now requested for the 2012 – 2013 Fellowship and Young Investigator award cycle. Overall, there will be a minimum of three awards of $40,000 per year, each for a duration of two years (total $80,000 per grant), with at least one recipient from each region (North America, Europe and Rest of the World) funded. The Prevent Cancer Foundation (PCF) will jointly sponsor awards focused on lung cancer prevention and translational research, supported through educational grants from Eli Lilly. Additional unrestricted awards in any field of lung cancer research are supported by educational grants from Amgen, Genentech, Celgene, Merck KGaA, Eli Lilly, the IASLC and other sponsors.

The goal is to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine. Applications will be evaluated by a Scientific Review Panel for their merit, innovation and potential impact on the management of lung cancer. The deadline for submission is January 16, 2012. A decision on applications will be reached by March 2012.

Application forms can be found at the website:

Please e-mail you application to: no later than January 16, 2012.

Please remember to pay the IASLC membership fee 2012 - $200

Registering online is fast and easy! Visit for more information. 
IASLC members will be sent renewal reminders and invoices. Register now so there will no interruption to your JTO subscription, and to receive discounts on 2012 meeting fees. Please contact the Membership Department if you need any assistance paying your dues:, or call +1.303.724.3159.

FREE IASLC Membership for Fellows:

Did you know that IASLC offers a FREE membership for fellows? This complimentary membership includes online access to the JTO, as well as additional discounts and educational programs. It is a great way to expose clinical fellows to the benefits of IASLC membership and introduce them to IASLC activities. The complimentary Fellow membership is available for a maximum of two years, and requires a verification letter from the program director stating the term dates of the fellowship. Please forward this link to any fellows you know and encourage them to join immediately:

IASLC Committees 2011 – 2012

Award Peter Goldstraw
Bylaw George Simon
Communications Heather Wakelee
Education Primo Lara
Ethics Kwun Fong
Fellowship Phil Mack
Finance  Fred R. Hirsch
Membership Nise Yamaguchi
Nominations Kathy Albain
Pathology Ming Tsao
Prevention, Screening & Early Detection John Field
Publications Glenwood Goss
Staging Ramon Rami-Porta
Advocates New TBD
Career Development New TBD
Nurses & Allied Professionals New TBD
















AACR IASLC Joint Conference – January 8-11, 2012

 aacr 2012

For further information: or


3rd ELCC (ESMO/IASLC) Lung Cancer Conference,
April 18 – 21, 2012, Geneva, Switzerland

 ELCC 2012

Abstracts deadline – January 11, 2012
For more information

5th Latin American Conference on Lung Cancer

 lalca 2012

The 5th Latin American Conference is now under planning and both an exciting educational – and scientific program have been developed, including sessions on the new staging, lung cancer screening and molecular testing for personalized medicine. Abstract deadline is March 30, 2012. For more information or

News from Japan

During the 3 and 4th of November, the 52nd Annual Meeting of the Japan Lung Cancer Society was held in Osaka (Congress President: Dr. Hirohito Tada) and was attended by more than 3200 participants. President Tada hosted the “JLCS/IASLC Joint Symposium” during the meeting. The symposium included the participation of renowned clinical oncologists, thoracic surgeons, pathologists and radiation oncologists and clinicians from Japan and other countries. The two-day program included presentations about combined modality for lung cancer and molecular-targeted therapy by distinguished guests from IASLC and JLCS. 

Symposium 1 (Nov 3): Combined modality for locally advanced NSCLC 

Chairs: Dr. Hisao Asamura (National Cnacer Center) and Dr. Hiromasa Nishimura (Kinki University)
Dr. Katsuyuki Kiura (Okayama University) gave a lecture on “Long-term follow-up of phase III trial of docetaxel and cisplatin versus mitomycin, vindesine, and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: Okayama Lung Cancer Study Group 0007”.
Dr. Ichiro Yoshino (Chiba University) presented on “Feasibility of induction therapy using concurrent cisplatin/S1/radiation followed by surgery for clinical stage III-N2 non-small cell lung cancer”.
Dr. Karen Kelly (University of California Davis) discussed “Combined Modality Treatment for Locally Advanced Non-Small Cell Lung Cancer”.
Dr. Ritsuko Komaki (MD Anderson Cancer Center) lectured on the topic of “Post Operative Radiotherapy (PORT) for Patients with Stage III Non-Small Cell Lung Cancer with Persistent N2 Disease after Induction Chemotherapy: Do we need more personalized PORT ?”.
Dr. Walter Weder (University Hospital Zurich) presented a lecture on “Combined modality treatment for locally advanced NSCLC (stage III)”.

Symposium 2 (Nov 4): Molecular targeted therapy for NSCLC
Chairs: Dr. Tetsuya Mitsudomi (Aichi Cancer Center) and Dr. Seiji Yano (KanazawaUniversity)
Dr. Pasi A. Janne (Dana Farber Cancer Institute) presented “Mechanisms of acquired resistance to ALK kinase Inhibitors”.
Dr. Makoto Maemondo (Miyagi Cancer Center) presented “EGFR-TKI for non-small cell lung cancer harboring EGFR mutation.
Dr. Seiji Yano (Kanazawa University) presented “Receptor ligand-triggered resistance to molecular targeted drugs in lung cancer”
Dr. David S Ettinger (John Hopkins University) presented “Anti-angiogenic therapy for advanced non-small cell lung cancer (NSCLC)”.
Dr. Edward S. Kim (MD Anderson Cancer Center) presented “Molecular-targeted therapy for non-small cell lung cancer”.

A total of 440 members of the JLCS participated in the joint symposium and we want to thank the guests from the IASLC for their excellent presentations.

(Kindly submitted by IASLC Regents for Japan: Norihiko Ikeda and Shuji Sakai. To find more information or to contact the Regent in your area, please visit:

IASLC Web-based Education Programs

IASLC has introduced new educational programs on its Web site ( for its members and for healthcare professionals who are managing patients with lung cancer. The first program titled, “New Developments in Non-Small Cell Lung Cancer” features Professor Peter Goldstraw, MD, in a two-part presentation, that reviews the fundamentals of the new lung cancer staging system and examines the role of the TNM staging system of patients with small-cell lung cancer. The new, updated IASLC nodal staging map is also reviewed. In another presentation, Paul Bunn, Jr, MD, addresses the incorporation of molecular testing into the standard diagnostic workup of patients with NSCLC, and the selection of appropriate treatment for patients. The program concludes with case-study presentations by Drs. Bunn and Harvey I. Pass, illustrating the use of the new staging system and molecular testing.

Upcoming webinars include: “Clinical Implications of the New Adenocarcinoma Classification”

IASLC Staging Manual:

The IASLC Staging Manual and Handbook in Thoracic Oncologic has now surpassed 35,000 copies sold worldwide. In addition, the Staging Posters and Reference Cards continue to be popular reference aids of the 7th edition staging system for practitioners and tumor boards. IASLC members can continue to order these publications and products at special member pricing (; contact for further information).

In addition, translations of these publications have been completed or are in process in multiple languages: Chinese, Italian, Japanese, Polish, and Turkish. Discussions about future translations in Spanish, Arabic, and Russian are ongoing.

Staging Manual

iPhone/iPAD Staging Atlas

The new IASLC Staging Manual has been published in different formats. Several years of work from the IASLC Staging Committee and particularly the chair Dr. Peter Goldstraw, has resulted in a formal staging manual. The book and the “pocket-cards” can be ordered at

JTO Mobile options

JTO is available for your iPhone, Blackberry, or Android phone, in a view designed for easy reading on a small screen. Type into your phone’s browser to access the site. You can view current issue table of contents, most viewed articles, most emailed articles, or search across issues. If you have created a user name and password on the desktop version of, you can use that same log in information to view full text articles, complete with illustrations.

IASLC Textbook – Editor in Chief: 
Harvey I. Pass, MD

Lung Cancer Book

Lung Cancer Book from Lippincott: The Fourth Edition of Principles and Practice of Lung Cancer, edited by Harvey I. Pass, MD et al is now available. For more information about the 1040 page book, with 330 illustrations (ISBN-10:0-7817-7365-2) or



John Wetherington

John Wetherington, IASLC CFO/COO is responsible for managing the operations, financial and administrative functions for the organization. He has more than 20 years' experience in executive and financial leadership roles at nonprofit organizations. Most recently he served as CFO for the Association of Hole in the Wall Camps supporting 27worldwide camps and programs for children with life-threatening diseases. He has bachelor degrees from the University of Colorado, a master's in business administration (MBA) from the University of Denver and a doctorate from the University of Phoenix. He is a certified public accountant (CPA).


LUNGevity Foundation announces the issuance of its 2012 RFA for its Career Development Awards for Translational Research. Research projects are restricted to translational lung cancer research. The award will be open to junior faculty members who are within the first five years of their faculty appointment. Career Development Awards may be for a maximum of $100,000 per year for three years. with the possibility of reapplying at the end of the term for an additional two years. The RFA will be posted by Monday, November 21, at and on proposalCentral at For more information, contact Margery Jacobson at or 312-464-0716.

Upcoming IASLC Workshops/Meetings 2011- 2015

AACR-IASLC Joint Conference: Lung Cancer
January 8-12, 2012
Location: San Diego, California, U.S.A.
Thoracic Malignancy Conference

January 14-16, 2012
12th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting
February 22-25, 2012
Location: Santa Monica, California, U.S.A.

3rd European Lung Cancer Conference

April 18 - 21, 2012

Location: Geneva, Switzerland
More information:

5th Latin American Lung Cancer Conference
July 25-27, 2012
Location: Rio de Janeiro, Brazil
More information:

Chicago Multidisciplinary Symposium in Thoracic Oncology
September 6-8, 2012
Location: Hotel Marriott, Chicago, Illinois, U.S.A.
More information:

5th Asia Pacific Lung Cancer Conference
November 26-28, 2012
Location: Hilton Sea Hawk, Fukuoka, Japan
More information:

15th World Conference on Lung Cancer
October 27-31, 2013
Location: Sydney, Australia
More information:

16th World Conference on Lung Cancer
September 4-8, 2015
Location: Denver, Colorado, USA
More information: